Syndrome News and Research

RSS
SARS-CoV-2 differs from other betacoronaviruses in a key IRE1α/XBP1 pathway

SARS-CoV-2 differs from other betacoronaviruses in a key IRE1α/XBP1 pathway

3 Jan 2022
Production of molecular probes of spike and subdomains for all SARS-CoV-2 variants

Production of molecular probes of spike and subdomains for all SARS-CoV-2 variants

3 Jan 2022
The impact of natural selection on sequence diversity in SARS-CoV-2

The impact of natural selection on sequence diversity in SARS-CoV-2

3 Jan 2022
Modeling shows SARS-CoV-2 Omicron will place a severe burden on UK's health services

Modeling shows SARS-CoV-2 Omicron will place a severe burden on UK's health services

3 Jan 2022
CDC report shows COVID vaccines safe for children, serious side effects rare

CDC report shows COVID vaccines safe for children, serious side effects rare

3 Jan 2022
Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

3 Jan 2022
Recommended choline intake during pregnancy improves child's sustained attention

Recommended choline intake during pregnancy improves child's sustained attention

3 Jan 2022
T-cell responses to SARS-CoV-2 Omicron variant confer protection to vaccinated individuals

T-cell responses to SARS-CoV-2 Omicron variant confer protection to vaccinated individuals

3 Jan 2022
Genomic sequencing supports a long-term infection as source of SARS-CoV-2 Omicron

Genomic sequencing supports a long-term infection as source of SARS-CoV-2 Omicron

3 Jan 2022
SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

3 Jan 2022
Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

3 Jan 2022
Minimal nAb titers against Omicron in the elderly after 3rd dose

Minimal nAb titers against Omicron in the elderly after 3rd dose

3 Jan 2022
SARS-CoV-2 Omicron study on hamsters, shows virus results in a less severe disease

SARS-CoV-2 Omicron study on hamsters, shows virus results in a less severe disease

3 Jan 2022
Omicron surges in England especially in young

Omicron surges in England especially in young

3 Jan 2022
NAbs activity against SARS-CoV-2 variants, including Omicron, in an elderly vaccinated cohort

NAbs activity against SARS-CoV-2 variants, including Omicron, in an elderly vaccinated cohort

3 Jan 2022
Echinacea, a potent antiviral against SARS-CoV-2

Echinacea, a potent antiviral against SARS-CoV-2

3 Jan 2022
Study shows structural and functional aspects of antibody neutralization of SARS-CoV-2 Omicron variant

Study shows structural and functional aspects of antibody neutralization of SARS-CoV-2 Omicron variant

31 Dec 2021
TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

31 Dec 2021
Less severe clinical consequences of infection with SARS-CoV-2 Omicron variant

Less severe clinical consequences of infection with SARS-CoV-2 Omicron variant

31 Dec 2021
Exploring the increase in hACE2 binding affinity of SARS-CoV-2 Omicron variant

Exploring the increase in hACE2 binding affinity of SARS-CoV-2 Omicron variant

31 Dec 2021

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback